肝细胞癌治疗延迟与生存:多中心队列研究
该多中心回顾性队列纳入2010至2018年美国4个医疗系统诊断的1561例肝细胞癌患者,治疗延迟定义为诊断后超过90天开始首次治疗。22.9%患者出现治疗延迟,延迟与总生存无显著差异(HR 1.09,95%CI 0.87-1.37)。
要点
- 肝细胞癌治疗延迟(>90天)发生率为22.9%。
- BCLC 0期患者治疗延迟最频繁(31.1%)。
- 治疗延迟与总生存无显著差异(HR 1.09,95%CI 0.87-1.37)。
核心结论
- 超过90天的治疗延迟发生于超过五分之一的肝细胞癌患者,但未与生存显著差异相关。
研究设计与样本
- 回顾性队列研究,纳入2010至2018年美国4个医疗系统诊断的1561例肝细胞癌患者。
主要发现
- 357例(22.9%)患者发生治疗延迟,BCLC 0期延迟最频繁(31.1%),其次为A期(24.3%)、B期(22.6%)、C期(13.6%)。
- 男性(OR 0.68,95%CI 0.51-0.91)和BCLC C期(vs A期:OR 0.40,95%CI 0.25-0.63)更少发生延迟,BCLC 0期(vs A期:OR 1.56,95%CI 1.06-2.29)更易发生延迟。
- 6个月landmark分析中,延迟组与及时组生存无差异(HR 1.09,95%CI 0.87-1.37),中位生存分别为12.1个月(IQR 5.5-23.3)和14.6个月(IQR 5.1-30.0)。
临床怎么用
- 对于肝细胞癌患者,治疗延迟超过90天未显著影响生存,临床可据此评估延迟风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Although treatment delays have been reported for several cancers, fewer studies have described the prevalence, contributing factors, and impact on survival in patients with hepatocellular carcinoma (HCC). We aimed to evaluate these aspects in a multicenter cohort. METHODS: We conducted a retrospective cohort study of patients diagnosed with HCC from 2010 to 2018 across 4 US health systems. Treatment delay was defined as the first treatment >90 days after HCC diagnosis. Univariable and multivariable logistic regression analyses were performed to identify factors associated with treatment delays. The association between treatment delay and overall survival was evaluated using multivariable Cox regression analysis. RESULTS: Among 1,561 eligible patients (median age 61.7 years, 75.0% men, 65.5% Barcelona Clinic Liver Cancer [BCLC] stage 0/A), treatment delays occurred in 357 (22.9%) patients. Treatment delays were most frequent with BCLC stage 0 (31.1%), followed by stage A (24.3%), stage B (22.6%), and stage C (13.6%). Men (OR 0.68, 95% CI 0.51-0.91) and patients with BCLC stage C HCC (vs stage A: OR 0.40, 95% CI 0.25-0.63) were less likely to experience delays, whereas those with BCLC stage 0 (vs stage A: OR 1.56, 95% CI 1.06-2.29) were more likely to experience delays. In a 6-month landmark analysis, survival did not differ between delayed vs timely treatment (HR 1.09, 95% CI 0.87-1.37). Median survival from the 6-month landmark was 12.1 months (IQR: 5.5-23.3) and 14.6 months (IQR: 5.1-30.0) for the treatment delay and timely treatment groups, respectively. DISCUSSION: Treatment delays exceeding 90 days occurred in over one-fifth of patients but were not associated with significant differences in survival.
引用
- Jarrah M, Rich NE, Figueroa G, et al. Treatment Delays and Survival in Patients With Hepatocellular Carcinoma: A Multicenter Cohort Study. Am J Gastroenterol. 2026. PMID: 41562446. doi:10.14309/ajg.0000000000003923
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。